Long-term in vivo effects of rapamycin on humoral and cellular immune responses in the rat
DOI: 10.1016/S0171-2985(11)80238-X
Title: Long-term in vivo effects of rapamycin on humoral and cellular immune responses in the rat
Journal Title: Immunobiology
Volume: 188
Issue: 3
Publication Date: July 1993
Start Page: 303
End Page: 315
Published online: online 2 November 2011
ISSN: 0171-2985
Author: Huifang Chen13, Hongyu Luo2, Pierre Daloze13, Dasheng Xu1, Xiochuan Shan2, Gilles St-Louis24, Jiangping Wu24a

  • 1 Laboratory of Experimental Surgery

  • 2 Laboratory of Nephrology and Transplantation Immunology of the Service of Nephrology, Notre-Dame Research Center

  • 3 Department of Surgery

  • 4 Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
  • Abstract: n (RAPA) is a strong immunosuppressant and is able to prevent allograft rejection in animal models. We have demonstrated that RAPA could strongly inhibit in vitro immunoglobulin (Ig) production by human lymphocytes. The present study investigated the Long-term in vivo effect of RAPA on humoral and cellular immune responses, and the effect of RAPA on accelerated rejection. It was shown that RAPA strongly inhibited antigen (Ag) specific antibody (AB) production (i.e. cytotoxic Ab to donor lymphocytes and Ab to tetanus toxoid) during the period of drug administration. The accelerated rejection of cardiac allografts in presensitized animals was alleviated by RAPA administration. These results suggest the potential application of RAPA in treatment of presensitized candidates for organ transplantation. A little more than two months after the drug withdrawal, the rats were basically competent in Ab response to further Ag challenges. When tested 4 months after the RAPA-treatment, the rats showed uncompromised cardiac allograft rejection, and the cellular immune response in vitro according to mixed lymphocyte reaction (MLR) and mitogen-stimulated proliferation were not hampered. Such results suggest that the immune system can return to normal status without sequelae after discontinuation of RAPA.
    Accepted: 12 March 1993
    Received: 20 October 1992
    Abbreviations: RAPA, Rapamycin; CsA, cyclosporin A; Ag, antigen; Ab, antibody; Ig, immunoglobulin; i.m., intramuscular; i.p., intraperitoneal; TT, tetanus toxoid; BUF, Buffalo; WFu, Wistar-Furth; LEW, Lewis; MST, mean survival time

    Please Share this Paper with friends:
    Comment Content
    User Name
    Post new Comment
    Post to Facebook
    Search Full Text